Nutex Health (NUTX) announced that its board of directors has approved an extension of the previously authorized stock repurchase program. The program, originally announced on August 14, authorized the repurchase of up to $25M of the company’s common stock over a six-month period, commencing upon the filing of the company’s Form 10-Q for the quarter ended June 30. The board has extended the program through March 31, 2026. The repurchase plan will be implemented in accordance with the provisions of Rule 10b-18 under the Securities Exchange Act of 1934, as amended, and under a Rule 10b5-1 trading plan, which is scheduled to go into effect on or about December 4.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NUTX:
- Nutex Health says ‘Capybara Research as an entity seems not to exist’
- Capybara Research believes Nutex Health engaged in fraudulent business practices
- Clinigence Holdings Files Auditors’ Consent for Nutex
- Nutex Health Inc. Reports Strong Revenue Growth
- Nutex Health reports Q3 EPS $7.76 vs. ($1.72) last year